54th Annual Meeting of
The American Association for the Study of Liver Diseases October 24, 28- 2003 Boston, Massachusetts
INDEX
HIV-HBV Coinfected Patients Show Sustained Suppression of Epivir-HBV-resistant HBV Through 3 Years of Treatment with Hepsera 10/29/03 Report Confirms Safety of Liver Transplantation in HIV-HCV Co-infected Patients 10/29/03 GB Virus C (GBV-C) Clearance Is Frequent in HIV-HCV Coinfected Patients Receiving Interferon and Ribavirin and Does Not Elevate HIV RNA Levels 10/29/03
HIV-HCV Coinfection Status Does Not Affect HCV Viral Kinetic Response to Interferon 11/10/03
Page Two
Age and Adherence Are Significant Predictors of HCV Treatment Success 10/29/03
RANTES Haplotypes Predictive of Sustained Virological Response to HCV Treatment 10/31/03
Results of Long-term Follow Up of Sustained Responders to Interferon Therapy in Chronic HCV Patients: A Meta-analysis 11/10/03
A Dynamic Model to Predict Sustained Virological Response to Combination Treatment with Pegasys and Copegus in Patients with Chronic HCV 11/19/03
Page Three
Rapid Viral Decline with Pegasys/Ribavirin in HCV Genotype 1 Is Associated with Enhanced HCV-specific T-cell Reactivity 10/29/03
Pegasys Plus Ribavirin Demonstrates Good Safety and Tolerability Profiles in African Americans with Chronic HCV Genotype 1 11/03/03 Pegasys Plus Ribavirin Produces a Benefit Regarding Histologic Response Among African Americans and Caucasians with Chronic HCV Genotype 1 11/03/03
Combination Treatment with Pegasys and Copegus Significantly Enhances Sustained Virological and Biochemical Response Rates in Patients with Chronic Hepatitis C Genotype 4 11/05/03
Daily and Higher Initial Dosing of Consensus Interferon (Infergen) May Be a Worthwhile Alternative to Peginterferon + Ribavirin in Genotype 1 HCV Patients with High HCV RNA 11/07/03
Racial Differences in HCV Disease Severity Between African American and Caucasian American Patients with HCV Genotype 1 11/19/03
Page Four
HIV-HCV Coinfection Status Does Not Affect HCV Viral Kinetic Response to Interferon 11/10/03 Multivariate Models Predict Outcome of Therapy for HCV at Baseline and at Weeks 4 and 8 11/07/03
Page Five
Delivery of Consensus Interferon (Infergen) by Continuous Pump Shows Substantial Reduction of HCV RNA Levels Among Nonresponder HCV Patients 11/07/03
61% of Prior Nonresponders Experience Early Virological Response after 12 Weeks of Triple Therapy with Zadaxin (thymalfasin) + Pegasys + Ribavirin: Interim Results of a Pilot Study 11/10/03
In Nonresponders at Week 48, High Dose PEG-Intron (3.0 mcg/kg/wk) Plus Ribavirin Produces Similar Viral Clearance Rate as Standard Dose (1.5 mcg/kg/wk): The Renew Trial 11/17/03
HCV-specific Immune Responses at Baseline Do Not Predict a Favorable Retreatment Outcome in Patients with Advanced Disease 11/21/03 Page Six
ALT Flares Are Not Necessary for a Significant Response to Therapy with Roferon or Pegasys in Patients with HBeAg positive Chronic Hepatitis B 11/05/03
In Patients 65 Years or Older, Chronic HCV Is More Severe and Presents with Lower ALT Levels Than in Younger Patients 11/10/03
Qualitative Tests (QLFTS) Detect Impaired Hepatic Function in a High Proportion of Patients with Chronic HCV and Fibrosis or Cirrhosis and May Predict Risk of Cirrhosis, Splenomegaly and Varices 11/17/03
Page Seven
Visual Problems May Not Completely Resolve in All Patients After Discontinuing Treatment with Peginterferon and Ribavirin: Observations from the WIN-R Trial 11/10/03
Viramidine, a Prodrug of Ribavirin, May Have Increased Efficacy and Reduced Red Blood Cell Toxicity Compared to Ribavirin 11/14/03
Predictors of Antiretroviral-related Severe Liver Toxicity in 21 AACTG Studies 11/07/03 Description of Liver Toxicity Associated with HIV Protease Inhibitors with or without Low-dose Ritonavir Boosting 11/07/03
Page Eight
At 24 Weeks, a Ribavirin Dose of 1000mg/day Appears to Offer No Advantages Over a Dose of 800mg/day in HIV-HCV Coinfected Patients 11/10/03
Page Nine
Race, Insulin Resistance, Visceral Adiposity and Hepatic Steatosis in Genotype 1 HCV Patients 10/29/03
As HAART Therapy Prolongs Survival, More HIV-HCV Coinfected Individuals May Experience Morbidity and Death from Progressive Liver Disease 11/07/03 PEG-Intron Plus Ribavirin Improves Histology and Fibrosis in Nonresponders to Conventional Interferon and Ribavirin 11/07/03
Treatment with Pirfenidone for One Year Produces a Significant Reduction in Necroinflammation and Steatosis in Patients with Liver Cirrhosis 11/19/03
HCV-specific Immune Responses at Baseline Do Not Predict a Favorable Retreatment Outcome in Patients with Advanced Disease 11/21/03
Epoetin Alfa Significantly Improves Quality of Life in HCV Patients Receiving Interferon plus Ribavirin and May Improve Adherence to Therapy 11/12/03
Page 10
Safety and Antiviral Effect of BILN 2061, an HCV Protease Inhibitor, After Treatment in HCV Genotype 1 Patients with Liver Cirrhosis 10/29/03
Antiviral Effect and Safety of Experimental HCV PI BILN 2061 After Oral Treatment in Non Genotype 1 Patients 10/29/03
Discovery of VX-950, an HCV Protease Inhibitor and a Potential Therapy for Chronic Hepatitis C 10/29/03
HCV Protease Inhibitor VX-950 Appears Effective in Early Studies 10/29/03
VX-950 Retains Potency Against BILN-2061-resistant Replicon Cells 10/29/03
SCH 6 Is a Potent Inhibitor of HCV Replication in vitro and May Be an Effective Protease Inhibitor for HCV Patients 10/29/03
HCV Polymerase Inhibitors Are Potential Drug Candidates for Treatment of HCV 10/29/03
Amantadine Does Not Improve the End of Therapy Response Rate When Added to Peginterferon and Ribavirin 10/29/03
RNA Interference: A New Strategy for HCV Treatment 10/31/03
RNA Interference Can Inhibit HCV Replication 10/31/03
Pegasys Plus Ribavirin Is More Effective Than Pegasys Plus Amantadine in Treatment-Naïve Patients with Chronic HCV 11/03/03
Evaluation of Pharmacokinetics, Safety, Immunogenicity and Pharmacodynamics of Albuferon in Nonresponders to Prior HCV Therapy 11-07-03
Treatment with Pirfenidone for One Year Produces a Significant Reduction in Necroinflammation and Steatosis in Patients with Liver Cirrhosis 11/19/03 Viramidine, a Prodrug of Ribavirin, May Have Increased Efficacy and Reduced Red Blood Cell Toxicity Compared to Ribavirin 11/14/03
Page 11
Baseline Psychosocial Characteristics of African Americans and Caucasian Participants Enrolled in the Virahep-C Study 11/19/03
Study Estimates in Year 2030, Deaths from HIV in the US Will Decline to 4,200 - 6,700, While HCV-related Deaths Will Peak at 14,000 - 19,000 11/14/03
Therapy Intolerance Is Problematic in Patients with Recurrent HCV Following Liver Transplant10/31/03
Liver Transplant Outcomes in HCV-infected Patients Are Unchanged from 1991 to 2001 10/31/03
Preemptive Therapy May Provide Important Histological Benefits in HCV Positive Liver Transplant Recipients 11/05/03 Patients with Recurrent HCV After Liver Transplantation Treated Have High Rates of Intolerance to Therapy with Peginterferon Plus Ribavirin 11/03/03 PEG-Intron Plus Ribavirin Appears to Improve the Clinical Course of HCV Reinfection After Liver Transplantation 11/05/03
PEG-Intron Plus Ribavirin Improves Histology and Fibrosis in Nonresponders to Conventional Interferon and Ribavirin 11/07/03